W. Boersma (Alkmaar, The Netherlands), M. Tamm (Basel, Switzerland)
Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia
E. M. W. van de Garde, H. Endeman, V. H. M. Deneer, D. H. Biesma, F. A. Sayed-Tabatabaei, H. J. T. Ruven, H. G. M. Leufkens, J. M. M. van den Bosch (Nieuwegein, Utrecht, The Hague, Netherlands)
|    |
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 groups at risk
S. Krueger, S. Ewig, R. Marre, J. Papassotiriou, K. Richter, N. Suttorp, T. Welte (Ulm, Bochum, Hennigsdorf, Berlin, Hannover, Germany)
| |
Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia
S. Krueger, J. Papassotiriou, R. Marre, K. Richter, C. Schumann, N. Suttorp, T. Welte (Ulm, Hennigsdorf, Berlin, Hannover, Germany)
| |
How much time does urinary legionella antigen excretion need to be negative in an outbreak?
J. A. Cascante, P. Cebollero, J. Hueto, J. Abu-shams, B. Fernandez, B. Marin (Pamplona, Spain)
| |
The prognostic importance of plasma D-dimer levels in patients with community acquired pneumonia
F. Alatas, C. Naz, G. Ak, H. Yildirim, M. Metintas, S. Erginel (Eskisehir, Turkey)
| |
Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
R. Menéndez, M. Cavalcanti, S. Reyes, R. Martínez, J. Mensa, X. Filella, A. Torres (Valencia, Barcelona, Spain)
| |
Admission glucose concentrations independently predict early mortality in patients with community-acquired pneumonia
S. Krueger, R. Marre, K. Richter, N. Suttorp, T. Welte (Ulm, Berlin, Hannover, Germany)
| |
Factors related to obtain an etiological diagnosis in community acquired pneumonia (CAP)
A. L. Andreu, E. Fernandez-Fabrellas, A. Cervera, M. C. Aguar, J. Blanquer, F. Tatay, R. Blanquer, F. Sanz, M. L. Briones (Comunidad, Valenciana, Spain)
| |